/Neurophet pushes Alzheimer’s imaging AI into Southeast Asia with new AQUA data
NEWS

Neurophet pushes Alzheimer’s imaging AI into Southeast Asia with new AQUA data

Korea Biomedical Review
2025/12/09

Korean AI brain imaging company Neurophet is betting that tighter imaging and monitoring can help shape the next wave of Alzheimer’s care in Southeast Asia, backing its push with new real-world and cohort data for its Neurophet AQUA platform at a regional dementia meeting in Singapore

Lim Hyun-kook, chief medical officer of Neurophet, delivering a presentation at the SEACURE symposium. (Courtesy of Neurophet)

At a symposium hosted Nov. 28 by the Southeast Asian Consortium on Neurocognition, Neuroimaging and Biomarker Research (SEACURE) at Nanyang Technological University’s Lee Kong Chian School of Medicine, Neurophet highlighted Neurophet AQUA AD, a software tool that supports monitoring of Alzheimer’s treatment decisions, therapeutic effect and adverse events.

The company ran an exhibition booth and presented clinical use cases alongside external validation data from a Southeast Asian cohort.

Neurophet’s chief medical officer, Lim Hyun-kook, who also leads the Catholic Brain Health Center at Yeouido St. Mary’s Hospital in Seoul, walked through Korean real-world cases in a talk titled “Neurophet a Game-Changer in Clinical Practice: Real-World Cases of Dementia Treatment Efficacy & Side Effect Management.”

Lim focused on how clinicians have used Neurophet AQUA AD in routine practice to track treatment response and improve safety around Alzheimer’s drug administration.

Providing an external lens, dementia specialist Nagaendran Kandiah, a professor at the Lee Kong Chian School of Medicine, presented data under the title “Automatic Brain Segmentation in Cognitive Impairment: Validation of AI-based AQUA Software in the Southeast Asian BIOCIS Cohort.”

His findings supported the clinical validity of Neurophet AQUA, a neurodegeneration imaging analysis tool, in patients with mild cognitive impairment and dementia enrolled across the regional BIOCIS study.

Neurophet said about 220 neurologists from six countries, including Singapore, Indonesia, Malaysia, the Philippines, Thailand and Vietnam, attended the SEACURE meeting.

Summary

Korean AI brain imaging company Neurophet is betting that tighter imaging and monitoring can help shape the next wave of Alzheimer’s care in Southeast Asia, backing its push with new real-world and cohort data for its Neurophet AQUA platform at a regional dementia meeting in Singapore At a symposium